Document Detail

An assessment of regression of left ventricular hypertrophy following alcohol ablation of the interventricular septum in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.
MedLine Citation:
PMID:  22933209     Owner:  NLM     Status:  In-Data-Review    
Background: Hypertrophic obstructive cardiomyopathy (HOCM) is characterised by asymmetric myocardial hypertrophy, which is most pronounced in the interventricular septum (IVS) and is responsible for the dynamic obstruction of the left ventricular outflow tract (LVOT). Successful alcohol septal ablation (ASA) of the IVS allows to reduce the thickness of the parabasal part of the IVS myocardium and, in most cases, to permanently reduce the gradient in the LVOT.〈/p〉 Aim: To assess, using cardiac magnetic resonance imaging (MRI) and transthoracic echocardiography (TTE), the impact of gradient reduction in the LVOT on the type and severity of left ventricular (LV) remodelling.〈/p〉 Methods: The study included 30 patients (aged 56.9 ± 11.9 years) with HOCM and the mean peak gradient (PG) in the LVOT of 123 ± 33 mm Hg who underwent ASA. MRI measurements were performed before and at 6 months after ASA and TTE measurements were performed before, at 3 months and at 6 months after ASA.〈/p〉 Results: PG in the LVOT decreased to an average of 52 ± 37 mm Hg (p 〈 0.0001) at 3 months after ASA and to 37 ± 28 mm Hg (p 〈 0.0001) at 6 months after ASA. TTE revealed a decrease in IVS thickness outside the scar following ASA from 23.6 ± 3.5 mm to 19.3 ± 4.0 mm (p 〈 0.0001) and 19.4 ± 0.4 mm (p 〈 0.0001) at 3 and 6 months, respectively. There was also a decrease in lateral wall (PW) thickness from 15.9 ± 3.2 mm to 14.9 ± 2.9 mm (p = 0.046) and 14.16 ± 2.00 (p = 0.0065) at 3 and 6 months, respectively. MRI revealed a decrease in IVS thickness from 23.7 ± 2.8 mm to 18.04 ± 4.00 mm (p = 0.0001) at 6 months following ASA. We observed a regression of the PW hypertrophy from 13.2 ± 3.35 mm to 12.18 ± 2.4 mm (p = 0.0225). There was a decrease in IVS mass from 108.9 ± 20 g to 91.5 ± 29 g (p = 0.0006). There was a trend towards a decreased LV mass and LV mass excluding IVS mass at 6 months.〈/p〉 Conclusions: A significant decrease in PG in the LVOT is associated with a decrease in LV mass and with regression of LV hypertrophy outside the scar after ASA.〈/p〉
Maciej Dąbrowski; Lidia Chojnowska; Lukasz Małek; Mateusz Spiewak; Beata Kuśmierczyk; Jacek Koziarek; Anna Klisiewicz; Jolanta Miśko; Adam Witkowski
Related Documents :
4499919 - Short- and long- term prognosis after myocardial infarction.
7349939 - In-hospital prognosis of patients with first nontransmural and transmural infarctions.
869279 - Long-term results of the medical treatment of coronary artery disease.
2688889 - Long-term follow-up of operated congenital heart disease.
125539 - Left main coronary arterial obstruction: long-term follow-up of 141 nonsurgical cases.
132089 - Chronic myocardial disease. i. clinical picture related to long-term prognosis.
11583899 - Pause-dependent torsade de pointes following acute myocardial infarction: a variant of ...
11515899 - Peroxynitrite formation from human myocardium after ischemia-reperfusion during open he...
449039 - The echocardiogram after pericardiectomy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Kardiologia polska     Volume:  70     ISSN:  0022-9032     ISO Abbreviation:  Kardiol Pol     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376352     Medline TA:  Kardiol Pol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  782-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Participation in thrombolytic trials delays reperfusion therapy in acute myocardial infarction.
Next Document:  Frequency spectra analysis suggests outcomes in patients with paroxysmal atrial fibrillation.